Application of anti-angiogenic therapy in non-small cell lung cancer
10.3969/j.issn.1000-8179.2018.19.755
- VernacularTitle:进展期非小细胞肺癌抗血管生成治疗进展
- Author:
Zhongtai WANG
1
;
Fang WU
;
Binjie YAN
;
Jingjing QU
;
Yongchang ZHANG
;
Nong YANG
Author Information
1. 南华大学研究生院
- Keywords:
non-small cell lung cancer;
angiogenesis;
anti-angiogenesis;
targeted therapy;
immunotherapy
- From:
Chinese Journal of Clinical Oncology
2018;45(19):973-979
- CountryChina
- Language:Chinese
-
Abstract:
Non-small cell lung cancer (NSCLC) accounts for 85% of total cases of lung cancer, which has the highest incidence and mor-tality in China. Most patients with lung cancer present with advanced stage disease at the time of diagnosis. With the limited develop-ment of cytotoxic chemotherapy for NSCLC therapy, median overall survival in patients receiving platinum-based doublet chemothera-py has been less than one year in several trials. To date, anti-angiogenesis agents combined with chemotherapy, small molecule tyro-sine kinase inhibitors (TKI) and immune checkpoint inhibitors were commonly applied in NSCLC instead of purely chemotherapy, which makes a great breakthrough in NSCLC therapy. This review summarizes and discusses the application of anti-angiogenic therapy in ad-vanced NSCLC.
